I attended the Verona Pharma AGM on Monday (June 27th) which was held at the offices of Shakespeare Martineau LLP, 5th Floor, One America Square, Crosswall, London EC3N 2SG. For anyone who is unfamiliar with the company, Verona Pharma (VRP) are an AIM listed UK based biotech focused on developing new treatments for COPD, Asthma and other respiratory diseases. Their current market cap is around £32M and they have just one compound (RPL554) in their portfolio which is being developed primarily for COPD but Asthma and Cystic Fibrosis indications should follow. Verona have demonstrated proof of concept for COPD and asthma in a series of Phase II studies and they now intend to conduct further phase II studies in order to define the clinical profile before progressing to phase III.
...Not a member? Join today
Joining ShareSoc helps to empower our collective voice in representing investors, but we also offer exclusive benefits:
Member events & Masterclasses
Regular newsletter
Member only on-line Forums / Q&As
Company data and Voting Guidance
Educational resources
Get involved in our activities
Already a member?
Log in to your account to access this content and all of your other ShareSoc membership benefits.